SAN DIEGO, January 10, 2021 (GLOBE NEWSWIRE) – Bionano Genomics, Inc. (Nasdaq: BNGO) announced the launch of its 5-day Next Generation Cytogenomics Symposium, which starts Monday, January 11 and will count with 33 presentations by Saphyr users differentiated from the main hospitals and medical research institutions worldwide. The presentations will cover optical genome mapping (GMO) applications with Saphyr to analyze the genomes of patients with a variety of genetic diseases, blood cancers, solid tumors and repeated diseases, as well as studies supporting the validation of clinical trials developed by Saphyr users. The last day of the symposium is dedicated to the study of the genomes of critically ill patients with COVID-19. The event is being held virtually and ends on January 15, 2021.
Alka Chaubey, FACMG, PhD, Chief Medical Officer of Bionano Genomics commented: “I joined Bionano Genomics in August 2020 because I believed that Saphyr was finally ready to transform the way genomes are analyzed in cancer and genetic diseases. I quickly realized that the research and clinical communities were not sufficiently aware of Saphyr’s capabilities as an informational tool for detecting structural variants of clinical importance. We created this symposium as part of our efforts to change that. I believe this event will be a turning point for Bionano Genomics, as we demonstrate the remarkable capabilities of the GMO with Saphyr and how it has the potential to become a standard platform in the arsenal of pathologists and researchers. “
Erik Holmlin, PhD, CEO of Bionano Genomics, commented: “In the past year, we have made tremendous progress in advancing Saphyr’s capabilities to detect the various classes of large genomic variants that are relevant in cancer and genetic diseases with high yield and low cost. in a simple workflow. Important recent data will be presented at our symposium, which we believe demonstrates that Saphyr can detect all structural variants reported clinically and identified by traditional cytogenetic methods, which short or long reading sequencing technologies have not been able to do. In addition to their equivalence with standard methods of care, presenters will illustrate how GMOs with Saphyr find additional variants lost by traditional methods, which has led to the diagnosis of more patients and an increase in diagnostic yield. We are excited to show the global community how Saphyr enables next generation cytogenomics. “
Each session lasts about 2.5 hours and starts at 7 am PST. After the scientific presentations, the speakers will gather for a live panel discussion and questions and answers moderated by Bionano’s medical director, Alka Chaubey. Upon completion of the live event, the recordings will be made available for viewing on demand.
Monday, January 11: Constitutional cytogenetics
This session begins with a presentation on Saphyr’s clinical validation studies compared to the standard of care cytogenetics for constitutional genetic diseases and prenatal testing. Additional speakers show how Saphyr can find pathogenic variants not detected by traditional methods for a variety of genetic diseases and disorders of sexual development.
Tuesday, January 12: Heme’s evil
Eight speakers from around the world will present the results of their studies comparing Saphyr with the cytogenetic standard of treatment for analyzing the genome of a variety of heme malignancies, including MDS, adult and pediatric ALL-B and leukemias CLL, ending with the presentation of the results of a major national multicentre assessment of acute myeloid leukemia.
Wednesday, January 13: solid tumor
In this session, the speakers will discuss their analysis of the structure of the solid tumor genome in head and neck cancer, non-inflammatory and inflammatory breast cancer, liver cancer, uveal melanoma, ending with an update on the development of a cancer LDT with Saphyr.
Thursday, January 14: Complex Molecular Diagnosis
This session returns to genetic diseases with a focus on repeated expansions and contractions and other complex molecular mechanisms. Hear how the image of Saphyr’s ultra-long DNA molecule can measure repeated contractions that cause FSHD, repeated expansions that cause spinocerebellar ataxia and adult familial myoclonic epilepsy, and can potentially solve other genetic mysteries.
Friday, January 15: SV Covid-19 Host Genome Expert Panel Session
Key members of the COVID-19 Host Genome SV Consortium will present how they are using Saphyr and other genomic technologies to detect structural variants in the human genome that may predispose to mild or severe COVID-19 disease. The speakers will present the study of 37 critically ill patients admitted to the ICU, children with MIS-C, comparative genomics of animals and people susceptible to SARS-CoV-2 infection and much more.
The full program of speakers and registration are available at http://bit.ly/3pLPT28
About Bionano Genomics
Bionano is a genome analysis company that provides tools and services based on its Saphyr system to scientists and doctors who conduct genetic research and patient testing and provides diagnostic tests for people with autism spectrum disorder (ASD) and other disabilities neurodevelopment through its Lineagen businesses. Bionano’s Saphyr system is an exclusive research use platform for detecting ultra-sensitive and ultra-specific structural variation that allows researchers and physicians to accelerate the search for new diagnostics and therapeutic targets and streamline the study of changes in chromosomes, which it is known as cytogenetics. The Saphyr system consists of an instrument, chip consumables, reagents and a set of data analysis tools and genome analysis services to provide access to the data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their laboratories . Lineagen has been providing genetic testing services to families and their healthcare providers for more than nine years and has performed more than 65,000 tests for those with neurodevelopment problems. For more information visit www.bionanogenomics.com or www.lineagen.com.
Forward-Looking Statements
This press release contains forward-looking statements in accordance with the meaning of the Private Securities Litigation Reform Act 1995. Words such as “may”, “will”, “wait”, “plan”, “anticipate”, “esteem”, “intends” And similar expressions (as well as other words or expressions that refer to future events, conditions or circumstances) convey uncertainty about future events or results and are intended to identify these forward-looking statements. Statements about future events include statements about our intentions , beliefs, projections, perspectives, analyzes or current expectations about, among other things: the timing and content of the presentations identified in this press release; the effectiveness and utility of Bionano’s technology in basic genetic research and clinical settings, and in contexts and applications covered by the presentations identified in this press release; adoption of Saphyr as a standard platform in research and pathology; and the execution of the Bionano strategy. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that can cause this difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient funding to finance our strategic plans and marketing efforts; the ability of medical and research institutions to obtain funding to support the adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our files with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended 31 December 2019 and in other filings subsequently made by us to the Securities and Exchange Commission. All forward-looking statements contained in this press release refer only to the date they were made and are based on management’s assumptions and estimates as of that date. We assume no obligation to publicly update any forward-looking statements, whether as a result of receiving new information, the occurrence of future events or otherwise.
CONTACTS
Company contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
[email protected]
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
[email protected]
Media contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
[email protected]